REG - Aptamer Group PLC - Results of 2023 Annual General Meeting

AptamerAnnouncement

15/12/2023 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231215:nRSO0395Xa&default-theme=true

RNS Number : 0395X  Aptamer Group PLC  15 December 2023

15 December 2023

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Results of 2023 Annual General Meeting

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, today announces that the
results of voting on the resolutions put to shareholders at its Annual General
Meeting ("AGM") held earlier today at 10:00 GMT at the offices of Aptamer
Group, Windmill House, Innovation Way, York, YO23 1LR, all Resolutions were
duly passed. Further details of each of the resolutions are set out in the
Notice of Meeting, which was sent to shareholders on 20 November and the full
poll results will be made available on the Aptamer website later today.

 

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Steve Hull
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Mark Brady / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion.

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGEELFFXLLEFBE